Literature DB >> 19131507

Constitutive somatostatin receptor activity determines tonic pituitary cell response.

Anat Ben-Shlomo1, Cuiqi Zhou, Oxana Pichurin, Vera Chesnokova, Ning-Ai Liu, Michael D Culler, Shlomo Melmed.   

Abstract

Somatostatin (SRIF) binds G protein-coupled SRIF receptor subtypes (SST1, -2, -3, -4, and -5) to regulate cell secretion and proliferation. Hypothalamic SRIF inhibits pituitary growth hormone, thyroid stimulating hormone, and ACTH secretion. We tested SRIF-independent constitutive SST activity in AtT20 mouse pituitary corticotroph cells in which ACTH secretion is highly sensitive to SRIF action. Stable transfectants expressing SST2 or SST5 were sensitized to selective agonist action, and constitutive SST receptor activity was demonstrated by forskolin and pertussis toxin cAMP cell responses. Persistent constitutive SST activity decreased cell ACTH responses to CRH through decreased expression of CRH receptor subtype 1. Decreased dopamine receptor type 1 expression was associated with attenuated dopamine agonist action, whereas responses to isoproterenol were enhanced through increased beta2-adrenoreceptor expression. Thus, integrated pituitary cell ACTH regulation is determined both by phasic SRIF action, as well as by tonic constitutive SST activity, independently of SRIF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19131507      PMCID: PMC2725764          DOI: 10.1210/me.2008-0361

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  48 in total

1.  Impairment in motor learning of somatostatin null mutant mice.

Authors:  T Zeyda; N Diehl; R Paylor; M B Brennan; U Hochgeschwender
Journal:  Brain Res       Date:  2001-07-06       Impact factor: 3.252

2.  Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice.

Authors:  C Viollet; C Vaillend; C Videau; M T Bluet-Pajot; A Ungerer; A L'Héritier; C Kopp; B Potier; J Billard; J Schaeffer; R G Smith; S P Rohrer; H Wilkinson; H Zheng; J Epelbaum
Journal:  Eur J Neurosci       Date:  2000-10       Impact factor: 3.386

3.  Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons.

Authors:  H Zheng; A Bailey; M H Jiang; K Honda; H Y Chen; M E Trumbauer; L H Van der Ploeg; J M Schaeffer; G Leng; R G Smith
Journal:  Mol Endocrinol       Date:  1997-10

Review 4.  Pituitary cytokine and growth factor expression and action.

Authors:  D Ray; S Melmed
Journal:  Endocr Rev       Date:  1997-04       Impact factor: 19.871

5.  Isolation and characterization of the gene encoding the type 5 mouse (Mus musculus) somatostatin receptor (msst5).

Authors:  A L Lublin; N L Diehl; U Hochgeschwender
Journal:  Gene       Date:  1997-08-11       Impact factor: 3.688

6.  Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growth.

Authors:  M J Low; V Otero-Corchon; A F Parlow; J L Ramirez; U Kumar; Y C Patel; M Rubinstein
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 7.  Somatostatin and its receptor family.

Authors:  Y C Patel
Journal:  Front Neuroendocrinol       Date:  1999-07       Impact factor: 8.606

8.  Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells.

Authors:  D Melck; D Rueda; I Galve-Roperh; L De Petrocellis; M Guzmán; V Di Marzo
Journal:  FEBS Lett       Date:  1999-12-17       Impact factor: 4.124

9.  Autoregulation of the human D1A dopamine receptor gene by cAMP.

Authors:  M T Minowa; S H Lee; M M Mouradian
Journal:  DNA Cell Biol       Date:  1996-09       Impact factor: 3.311

10.  Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways.

Authors:  Damián Kovalovsky; Damián Refojo; Ana Clara Liberman; Daniel Hochbaum; Marcelo Paez Pereda; Omar A Coso; Günter K Stalla; Florian Holsboer; Eduardo Arzt
Journal:  Mol Endocrinol       Date:  2002-07
View more
  14 in total

1.  hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.

Authors:  Richard W Mercier; Ying Pei; Lakshmipathi Pandarinathan; David R Janero; Jing Zhang; Alexandros Makriyannis
Journal:  Chem Biol       Date:  2010-10-29

Review 2.  Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.

Authors:  Stefan Schulz; Andreas Lehmann; Andrea Kliewer; Falko Nagel
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

4.  Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.

Authors:  X Fan; Z Mao; D He; C Liao; X Jiang; N Lei; B Hu; X Wang; Z Li; Y Lin; X Gou; Y Zhu; H Wang
Journal:  J Endocrinol Invest       Date:  2015-06-03       Impact factor: 4.256

5.  EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.

Authors:  Hidenori Fukuoka; Odelia Cooper; Anat Ben-Shlomo; Adam Mamelak; Song-Guang Ren; Dave Bruyette; Shlomo Melmed
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

Review 6.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

7.  Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function.

Authors:  Masaaki Yamamoto; Anat Ben-Shlomo; Hiraku Kameda; Hidenori Fukuoka; Nan Deng; Yan Ding; Shlomo Melmed
Journal:  JCI Insight       Date:  2018-10-04

Review 8.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

Review 9.  Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.

Authors:  Rossana Berardi; Francesca Morgese; Mariangela Torniai; Agnese Savini; Stefano Partelli; Silvia Rinaldi; Miriam Caramanti; Consuelo Ferrini; Massimo Falconi; Stefano Cascinu
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

Review 10.  Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.

Authors:  Richard A Feelders; Leo J Hofland; Maarten O van Aken; Sebastian J Neggers; Steven W J Lamberts; Wouter W de Herder; Aart-Jan van der Lely
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.